^
    Back
    Association details:
    Biomarker:TMB-L + PD-L1 expression
    Cancer:Neuroendocrine Tumor
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    Treatment of atypical pulmonary carcinoid with combination ipilimumab and nivolumab

    Published date:
    11/28/2019
    Excerpt:
    New biopsy analysis demonstrated APC with low mutational burden, low Ki-67 and Programmed Death-Ligand 1 (PD-L1), and without microsatellite instability….We pursued combination nivolumab and ipilimumab treatment based on success of CheckMate 032 in small-cell lung cancer. The patient’s symptoms dramatically responded within a month, with almost complete resolution of lymphadenopathy following four cycles. He has been successfully maintained on nivolumab for the last 18 months.
    DOI:
    10.1136/bcr-2019-231029